HUCK MEDICAL TECHNOLOGIES, INC.
– Public Announcement 06-20-19
Jack Merritt Joins Huck Medical Technologies Board Of Directors

Huck Medical Technologies (HMT), is pleased to announce the addition of Jack Merritt to the HMT team. Jack will be serving the as a Senior Advisor and Board Chair, bringing significant value to the organization.

Jack has over 30 years of broadly based sales, marketing and general management experience in the medical device industry. His experience includes 20 years with subsidiaries of Johnson and Johnson, and significant experience with early stage companies, in both domestic and international markets. Most recently, Jack was President and Chief Executive Officer of ICON Medical Corp., an early stage company developing innovative products for interventional cardiology.

Jack joined ICON in 2004 and led the company through several important stages of fundraising and product development. He successfully raised over $15 million in private funding, licensed a state-of-the-art drug and recruited internationally known clinical investigators. Jack also negotiated the out licensing of the first generation technology after achieving CE mark, providing substantial non-dilutive funding.

Prior to joining ICON, Jack served as President of the U.S. subsidiary and Co-Chairman of the Worldwide Operating Committee of Regent Medical, a highly differentiated surgical disposables business. At Regent he developed and implemented plans for profitable growth resulting in annual sales increases of 15-20% in a mature market. At the same time, operating expenses were reduced and customer fill rates were improved by implementing Vendor Managed Inventory programs. Jack also served on the Board of the Association of Operating Room Nurses Foundation during this time.

Earlier, Jack led the Sales and Marketing efforts of CardioGenesis Corporation, a startup in the Interventional Cardiology space. As Vice President, Sales and Marketing he was responsible for driving capital equipment sales into clinical trials, resulting in FDA approval of a new technology for cardiac revascularization. In addition, Jack directed the launch of a new device into the European market and managed the relationship with distribution partner, Boston Scientific Corporation. Jack joined Johnson and Johnson Interventional Systems in 1989, where he led startup activities in Europe. He recruited and hired the first vascular stent sales team in the U.S., and set up the sales management structure, including compensation and administrative functions. As Vice President, Sales and Marketing and member of the Worldwide Franchise Council, he led the sales and marketing team responsible for the most successful launch of a new device in medical products history, the Palmaz-Schatz Coronary Stent, resulting in $300 million domestic and $200 million international sales.

Currently Jack serves on the Board of Directors of the Bio/Med Investor Network, and is Chairman of the Screening Committee.

Jack holds a BBA degree from Georgia State University in Atlanta, and has completed Executive Programs at IMD in Lausanne, Switzerland and at INSEAD in Fountainebleu, France.